Skip to main content
Erschienen in: Calcified Tissue International 1/2014

01.07.2014 | Original Research

Deficiency in Perlecan/HSPG2 During Bone Development Enhances Osteogenesis and Decreases Quality of Adult Bone in Mice

verfasst von: Dylan A. Lowe, Nadia Lepori-Bui, Peter V. Fomin, Laura G. Sloofman, Xiaozhou Zhou, Mary C. Farach-Carson, Liyun Wang, Catherine B. Kirn-Safran

Erschienen in: Calcified Tissue International | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Perlecan/HSPG2 (Pln) is a large heparan sulfate proteoglycan abundant in the extracellular matrix of cartilage and the lacunocanalicular space of adult bones. Although Pln function during cartilage development is critical, evidenced by deficiency disorders including Schwartz–Jampel Syndrome and dyssegmental dysplasia Silverman-Handmaker type, little is known about its function in development of bone shape and quality. The purpose of this study was to understand the contribution of Pln to bone geometric and mechanical properties. We used hypomorph mutant mice that secrete negligible amount of Pln into skeletal tissues and analyzed their adult bone properties using micro-computed tomography and three-point-bending tests. Bone shortening and widening in Pln mutants was observed and could be attributed to loss of growth plate organization and accelerated osteogenesis that was reflected by elevated cortical thickness at older ages. This effect was more pronounced in Pln mutant females, indicating a sex-specific effect of Pln deficiency on bone geometry. Additionally, mutant females, and to a lesser extent mutant males, increased their elastic modulus and bone mineral densities to counteract changes in bone shape, but at the expense of increased brittleness. In summary, Pln deficiency alters cartilage matrix patterning and, as we now show, coordinately influences bone formation and calcification.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat French MM, Smith SE, Akanbi K, Sanford T, Hecht J, Farach-Carson MC, Carson DD (1999) Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro. J Cell Biol 145:1103–1115PubMedCentralPubMedCrossRef French MM, Smith SE, Akanbi K, Sanford T, Hecht J, Farach-Carson MC, Carson DD (1999) Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro. J Cell Biol 145:1103–1115PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Brown AJ, Alicknavitch M, D’Souza SS, Daikoku T, Kirn-Safran CB, Marchetti D, Carson DD, Farach-Carson MC (2008) Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation. Bone 43:689–699PubMedCentralPubMedCrossRef Brown AJ, Alicknavitch M, D’Souza SS, Daikoku T, Kirn-Safran CB, Marchetti D, Carson DD, Farach-Carson MC (2008) Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation. Bone 43:689–699PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y (1999) Perlecan is essential for cartilage and cephalic development. Nat Genet 23:354–358PubMedCrossRef Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y (1999) Perlecan is essential for cartilage and cephalic development. Nat Genet 23:354–358PubMedCrossRef
4.
Zurück zum Zitat Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W, Hunziker E, Addicks K, Timpl R, Fassler R (1999) Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol 147:1109–1122PubMedCentralPubMedCrossRef Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W, Hunziker E, Addicks K, Timpl R, Fassler R (1999) Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol 147:1109–1122PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Stum M, Davoine CS, Vicart S, Guillot-Noel L, Topaloglu H, Carod-Artal FJ, Kayserili H, Hentati F, Merlini L, Urtizberea JA, el Hammouda H, Quan PC, Fontaine B, Nicole S (2006) Spectrum of HSPG2 (Perlecan) mutations in patients with Schwartz–Jampel syndrome. Hum Mutat 27:1082–1091PubMedCrossRef Stum M, Davoine CS, Vicart S, Guillot-Noel L, Topaloglu H, Carod-Artal FJ, Kayserili H, Hentati F, Merlini L, Urtizberea JA, el Hammouda H, Quan PC, Fontaine B, Nicole S (2006) Spectrum of HSPG2 (Perlecan) mutations in patients with Schwartz–Jampel syndrome. Hum Mutat 27:1082–1091PubMedCrossRef
6.
Zurück zum Zitat Arikawa-Hirasawa E, Wilcox WR, Le AH, Silverman N, Govindraj P, Hassell JR, Yamada Y (2001) Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat Genet 27:431–434PubMedCrossRef Arikawa-Hirasawa E, Wilcox WR, Le AH, Silverman N, Govindraj P, Hassell JR, Yamada Y (2001) Dyssegmental dysplasia, Silverman-Handmaker type, is caused by functional null mutations of the perlecan gene. Nat Genet 27:431–434PubMedCrossRef
7.
Zurück zum Zitat Farach-Carson MC, Carson DD (2007) Perlecan—a multifunctional extracellular proteoglycan scaffold. Glycobiology 17:897–905PubMedCrossRef Farach-Carson MC, Carson DD (2007) Perlecan—a multifunctional extracellular proteoglycan scaffold. Glycobiology 17:897–905PubMedCrossRef
8.
Zurück zum Zitat Yang W, Gomes RR, Brown AJ, Burdett AR, Alicknavitch M, Farach-Carson MC, Carson DD (2006) Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices. Tissue Eng 12:2009–2024PubMedCentralPubMedCrossRef Yang W, Gomes RR, Brown AJ, Burdett AR, Alicknavitch M, Farach-Carson MC, Carson DD (2006) Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices. Tissue Eng 12:2009–2024PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Jha AK, Yang W, Kirn-Safran CB, Farach-Carson MC, Jia X (2009) Perlecan domain I–conjugated, hyaluronic acid–based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials 30:6964–6975PubMedCentralPubMedCrossRef Jha AK, Yang W, Kirn-Safran CB, Farach-Carson MC, Jia X (2009) Perlecan domain I–conjugated, hyaluronic acid–based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release. Biomaterials 30:6964–6975PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Burstein AH, Zika JM, Heiple KG, Klein L (1975) Contribution of collagen and mineral to the elastic–plastic properties of bone. J Bone Joint Surg Am 57:956–961PubMed Burstein AH, Zika JM, Heiple KG, Klein L (1975) Contribution of collagen and mineral to the elastic–plastic properties of bone. J Bone Joint Surg Am 57:956–961PubMed
11.
Zurück zum Zitat Oristian DS, Sloofman LG, Zhou X, Wang L, Farach-Carson MC, Kirn-Safran CB (2009) Ribosomal protein L29/HIP deficiency delays osteogenesis and increases fragility of adult bone in mice. J Orthop Res 27:28–35PubMedCentralPubMedCrossRef Oristian DS, Sloofman LG, Zhou X, Wang L, Farach-Carson MC, Kirn-Safran CB (2009) Ribosomal protein L29/HIP deficiency delays osteogenesis and increases fragility of adult bone in mice. J Orthop Res 27:28–35PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Ling Y, Rios HF, Myers ER, Lu Y, Feng JQ, Boskey AL (2005) DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J Bone Miner Res 20:2169–2177PubMedCentralPubMedCrossRef Ling Y, Rios HF, Myers ER, Lu Y, Feng JQ, Boskey AL (2005) DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J Bone Miner Res 20:2169–2177PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Wallace JM, Rajachar RM, Chen XD, Shi S, Allen MR, Bloomfield SA, Les CM, Robey PG, Young MF, Kohn DH (2006) The mechanical phenotype of biglycan-deficient mice is bone- and gender-specific. Bone 39:106–116PubMedCrossRef Wallace JM, Rajachar RM, Chen XD, Shi S, Allen MR, Bloomfield SA, Les CM, Robey PG, Young MF, Kohn DH (2006) The mechanical phenotype of biglycan-deficient mice is bone- and gender-specific. Bone 39:106–116PubMedCrossRef
14.
Zurück zum Zitat Boskey AL, Spevak L, Paschalis E, Doty SB, McKee MD (2002) Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 71:145–154PubMedCrossRef Boskey AL, Spevak L, Paschalis E, Doty SB, McKee MD (2002) Osteopontin deficiency increases mineral content and mineral crystallinity in mouse bone. Calcif Tissue Int 71:145–154PubMedCrossRef
15.
Zurück zum Zitat Boskey AL, Spevak L, Doty SB, Rosenberg L (1997) Effects of bone CS-proteoglycans, DS-decorin, and DS-biglycan on hydroxyapatite formation in a gelatin gel. Calcif Tissue Int 61:298–305PubMedCrossRef Boskey AL, Spevak L, Doty SB, Rosenberg L (1997) Effects of bone CS-proteoglycans, DS-decorin, and DS-biglycan on hydroxyapatite formation in a gelatin gel. Calcif Tissue Int 61:298–305PubMedCrossRef
16.
Zurück zum Zitat Miller E, Delos D, Baldini T, Wright TM, Pleshko Camacho N (2007) Abnormal mineral–matrix interactions are a significant contributor to fragility in oim/oim bone. Calcif Tissue Int 81:206–214PubMedCentralPubMedCrossRef Miller E, Delos D, Baldini T, Wright TM, Pleshko Camacho N (2007) Abnormal mineral–matrix interactions are a significant contributor to fragility in oim/oim bone. Calcif Tissue Int 81:206–214PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Thompson WR, Modla S, Grindel BJ, Czymmek KJ, Kirn-Safran CB, Wang L, Duncan RL, Farach-Carson MC (2011) Perlecan/Hspg2 deficiency alters the pericellular space of the lacuno-canalicular system surrounding osteocytic processes in cortical bone. J Bone Miner Res 26:618–629PubMedCentralPubMedCrossRef Thompson WR, Modla S, Grindel BJ, Czymmek KJ, Kirn-Safran CB, Wang L, Duncan RL, Farach-Carson MC (2011) Perlecan/Hspg2 deficiency alters the pericellular space of the lacuno-canalicular system surrounding osteocytic processes in cortical bone. J Bone Miner Res 26:618–629PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Wang B, Lai X, Price C, Thompson WR, Li W, Quabili TR, Tseng WJ, Liu XS, Zhang H, Pan J, Kirn-Safran CB, Farach-Carson MC, Wang L (2014) Perlecan-containing pericellular matrix regulates solute transport and mechanosensing within the osteocyte lacunar–canalicular system. J Bone Miner Res 29:878–891PubMedCrossRef Wang B, Lai X, Price C, Thompson WR, Li W, Quabili TR, Tseng WJ, Liu XS, Zhang H, Pan J, Kirn-Safran CB, Farach-Carson MC, Wang L (2014) Perlecan-containing pericellular matrix regulates solute transport and mechanosensing within the osteocyte lacunar–canalicular system. J Bone Miner Res 29:878–891PubMedCrossRef
19.
Zurück zum Zitat Rodgers KD, Sasaki T, Aszodi A, Jacenko O (2007) Reduced perlecan in mice results in chondrodysplasia resembling Schwartz–Jampel syndrome. Hum Mol Genet 16:515–528PubMedCrossRef Rodgers KD, Sasaki T, Aszodi A, Jacenko O (2007) Reduced perlecan in mice results in chondrodysplasia resembling Schwartz–Jampel syndrome. Hum Mol Genet 16:515–528PubMedCrossRef
20.
Zurück zum Zitat Kirn-Safran CB, Oristian DS, Focht RJ, Parker SG, Vivian JL, Carson DD (2007) Global growth deficiencies in mice lacking the ribosomal protein HIP/RPL29. Dev Dyn 236:447–460PubMedCrossRef Kirn-Safran CB, Oristian DS, Focht RJ, Parker SG, Vivian JL, Carson DD (2007) Global growth deficiencies in mice lacking the ribosomal protein HIP/RPL29. Dev Dyn 236:447–460PubMedCrossRef
21.
Zurück zum Zitat Miller SA, Brown AJ, Farach-Carson MC, Kirn-Safran CB (2003) HIP/RPL29 down-regulation accompanies terminal chondrocyte differentiation. Differentiation 71:322–336PubMedCrossRef Miller SA, Brown AJ, Farach-Carson MC, Kirn-Safran CB (2003) HIP/RPL29 down-regulation accompanies terminal chondrocyte differentiation. Differentiation 71:322–336PubMedCrossRef
22.
Zurück zum Zitat Schriefer JL, Robling AG, Warden SJ, Fournier AJ, Mason JJ, Turner CH (2005) A comparison of mechanical properties derived from multiple skeletal sites in mice. J Biomech 38:467–475PubMedCrossRef Schriefer JL, Robling AG, Warden SJ, Fournier AJ, Mason JJ, Turner CH (2005) A comparison of mechanical properties derived from multiple skeletal sites in mice. J Biomech 38:467–475PubMedCrossRef
23.
Zurück zum Zitat Bi Y, Stuelten CH, Kilts T, Wadhwa S, Iozzo RV, Robey PG, Chen XD, Young MF (2005) Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. J Biol Chem 280:30481–30489PubMedCrossRef Bi Y, Stuelten CH, Kilts T, Wadhwa S, Iozzo RV, Robey PG, Chen XD, Young MF (2005) Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. J Biol Chem 280:30481–30489PubMedCrossRef
24.
Zurück zum Zitat Chen CC, Boskey AL (1985) Mechanisms of proteoglycan inhibition of hydroxyapatite growth. Calcif Tissue Int 37:395–400PubMedCrossRef Chen CC, Boskey AL (1985) Mechanisms of proteoglycan inhibition of hydroxyapatite growth. Calcif Tissue Int 37:395–400PubMedCrossRef
25.
Zurück zum Zitat Rees SG, Shellis RP, Embery G (2002) Inhibition of hydroxyapatite crystal growth by bone proteoglycans and proteoglycan components. Biochem Biophys Res Commun 292:727–733PubMedCrossRef Rees SG, Shellis RP, Embery G (2002) Inhibition of hydroxyapatite crystal growth by bone proteoglycans and proteoglycan components. Biochem Biophys Res Commun 292:727–733PubMedCrossRef
26.
Zurück zum Zitat Shibata M, Shigematsu T, Hatamura I, Saji F, Mune S, Kunimoto K, Hanba Y, Shiizaki K, Sakaguchi T, Negi S (2010) Reduced expression of perlecan in the aorta of secondary hyperparathyroidism model rats with medial calcification. Ren Fail 32:214–223PubMedCrossRef Shibata M, Shigematsu T, Hatamura I, Saji F, Mune S, Kunimoto K, Hanba Y, Shiizaki K, Sakaguchi T, Negi S (2010) Reduced expression of perlecan in the aorta of secondary hyperparathyroidism model rats with medial calcification. Ren Fail 32:214–223PubMedCrossRef
27.
Zurück zum Zitat Zhou HY (2007) Proteomic analysis of hydroxyapatite interaction proteins in bone. Ann N Y Acad Sci 1116:323–326PubMedCrossRef Zhou HY (2007) Proteomic analysis of hydroxyapatite interaction proteins in bone. Ann N Y Acad Sci 1116:323–326PubMedCrossRef
28.
Zurück zum Zitat Stum M, Girard E, Bangratz M, Bernard V, Herbin M, Vignaud A, Ferry A, Davoine CS, Echaniz-Laguna A, Rene F, Marcel C, Molgo J, Fontaine B, Krejci E, Nicole S (2008) Evidence of a dosage effect and a physiological endplate acetylcholinesterase deficiency in the first mouse models mimicking Schwartz–Jampel syndrome neuromyotonia. Hum Mol Genet 17:3166–3179PubMedCrossRef Stum M, Girard E, Bangratz M, Bernard V, Herbin M, Vignaud A, Ferry A, Davoine CS, Echaniz-Laguna A, Rene F, Marcel C, Molgo J, Fontaine B, Krejci E, Nicole S (2008) Evidence of a dosage effect and a physiological endplate acetylcholinesterase deficiency in the first mouse models mimicking Schwartz–Jampel syndrome neuromyotonia. Hum Mol Genet 17:3166–3179PubMedCrossRef
29.
Zurück zum Zitat Wallace JM, Rajachar RM, Allen MR, Bloomfield SA, Robey PG, Young MF, Kohn DH (2007) Exercise-induced changes in the cortical bone of growing mice are bone- and gender-specific. Bone 40:1120–1127PubMedCentralPubMedCrossRef Wallace JM, Rajachar RM, Allen MR, Bloomfield SA, Robey PG, Young MF, Kohn DH (2007) Exercise-induced changes in the cortical bone of growing mice are bone- and gender-specific. Bone 40:1120–1127PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Price C, Herman BC, Lufkin T, Goldman HM, Jepsen KJ (2005) Genetic variation in bone growth patterns defines adult mouse bone fragility. J Bone Miner Res 20:1983–1991PubMedCrossRef Price C, Herman BC, Lufkin T, Goldman HM, Jepsen KJ (2005) Genetic variation in bone growth patterns defines adult mouse bone fragility. J Bone Miner Res 20:1983–1991PubMedCrossRef
31.
Zurück zum Zitat Jepsen KJ, Pennington DE, Lee YL, Warman M, Nadeau J (2001) Bone brittleness varies with genetic background in A/J and C57BL/6J inbred mice. J Bone Miner Res 16:1854–1862PubMedCrossRef Jepsen KJ, Pennington DE, Lee YL, Warman M, Nadeau J (2001) Bone brittleness varies with genetic background in A/J and C57BL/6J inbred mice. J Bone Miner Res 16:1854–1862PubMedCrossRef
32.
Zurück zum Zitat Maloul A, Rossmeier K, Mikic B, Pogue V, Battaglia T (2006) Geometric and material contributions to whole bone structural behavior in GDF-7-deficient mice. Connect Tissue Res 47:157–162PubMedCrossRef Maloul A, Rossmeier K, Mikic B, Pogue V, Battaglia T (2006) Geometric and material contributions to whole bone structural behavior in GDF-7-deficient mice. Connect Tissue Res 47:157–162PubMedCrossRef
33.
Zurück zum Zitat Wiren KM, Zhang XW, Toombs AR, Kasparcova V, Gentile MA, Harada S, Jepsen KJ (2004) Targeted overexpression of androgen receptor in osteoblasts: unexpected complex bone phenotype in growing animals. Endocrinology 145:3507–3522PubMedCrossRef Wiren KM, Zhang XW, Toombs AR, Kasparcova V, Gentile MA, Harada S, Jepsen KJ (2004) Targeted overexpression of androgen receptor in osteoblasts: unexpected complex bone phenotype in growing animals. Endocrinology 145:3507–3522PubMedCrossRef
34.
Zurück zum Zitat Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, Gaillard-Kelly M, Baron R (2002) Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone 30:18–25PubMedCrossRef Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, Gaillard-Kelly M, Baron R (2002) Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone 30:18–25PubMedCrossRef
35.
Zurück zum Zitat Oh JH, Kim YK, Jung JY, Shin JE, Chung JH (2011) Changes in glycosaminoglycans and related proteoglycans in intrinsically aged human skin in vivo. Exp Dermatol 20:454–456PubMedCrossRef Oh JH, Kim YK, Jung JY, Shin JE, Chung JH (2011) Changes in glycosaminoglycans and related proteoglycans in intrinsically aged human skin in vivo. Exp Dermatol 20:454–456PubMedCrossRef
36.
Zurück zum Zitat Smith SE, French MM, Julian J, Paria BC, Dey SK, Carson DD (1997) Expression of heparan sulfate proteoglycan (perlecan) in the mouse blastocyst is regulated during normal and delayed implantation. Dev Biol 184:38–47PubMedCrossRef Smith SE, French MM, Julian J, Paria BC, Dey SK, Carson DD (1997) Expression of heparan sulfate proteoglycan (perlecan) in the mouse blastocyst is regulated during normal and delayed implantation. Dev Biol 184:38–47PubMedCrossRef
Metadaten
Titel
Deficiency in Perlecan/HSPG2 During Bone Development Enhances Osteogenesis and Decreases Quality of Adult Bone in Mice
verfasst von
Dylan A. Lowe
Nadia Lepori-Bui
Peter V. Fomin
Laura G. Sloofman
Xiaozhou Zhou
Mary C. Farach-Carson
Liyun Wang
Catherine B. Kirn-Safran
Publikationsdatum
01.07.2014
Verlag
Springer US
Erschienen in
Calcified Tissue International / Ausgabe 1/2014
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-014-9859-2

Weitere Artikel der Ausgabe 1/2014

Calcified Tissue International 1/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.